Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: SARS-CoV-2 DNA Vaccine (ICCOV)
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immuno Cure 3 Limited
- Target Recruit Count
- 31
- Registration Number
- NCT05904054
- Locations
- 🇭🇰
Gleneagles Hospital Hong Kong, Wong Chuk Hang, Hong Kong
© Copyright 2025. All Rights Reserved by MedPath